HRP20180054T1 - Farmaceutski pripravci koji sadrže toksoide clostridium difficile a i b - Google Patents
Farmaceutski pripravci koji sadrže toksoide clostridium difficile a i b Download PDFInfo
- Publication number
- HRP20180054T1 HRP20180054T1 HRP20180054TT HRP20180054T HRP20180054T1 HR P20180054 T1 HRP20180054 T1 HR P20180054T1 HR P20180054T T HRP20180054T T HR P20180054TT HR P20180054 T HRP20180054 T HR P20180054T HR P20180054 T1 HRP20180054 T1 HR P20180054T1
- Authority
- HR
- Croatia
- Prior art keywords
- preparation
- sodium
- clostridium difficile
- toxoid
- sucrose
- Prior art date
Links
- 241000193163 Clostridioides difficile Species 0.000 title claims 16
- 239000008194 pharmaceutical composition Substances 0.000 title 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 claims 11
- 229930006000 Sucrose Natural products 0.000 claims 11
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 claims 11
- 239000000546 pharmaceutical excipient Substances 0.000 claims 11
- 239000005720 sucrose Substances 0.000 claims 11
- 239000001509 sodium citrate Substances 0.000 claims 9
- WSFSSNUMVMOOMR-NJFSPNSNSA-N methanone Chemical compound O=[14CH2] WSFSSNUMVMOOMR-NJFSPNSNSA-N 0.000 claims 8
- 239000000872 buffer Substances 0.000 claims 6
- 239000001508 potassium citrate Substances 0.000 claims 6
- 229960002635 potassium citrate Drugs 0.000 claims 6
- QEEAPRPFLLJWCF-UHFFFAOYSA-K potassium citrate (anhydrous) Chemical compound [K+].[K+].[K+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O QEEAPRPFLLJWCF-UHFFFAOYSA-K 0.000 claims 6
- 235000011082 potassium citrates Nutrition 0.000 claims 6
- 229910052708 sodium Inorganic materials 0.000 claims 6
- LWIHDJKSTIGBAC-UHFFFAOYSA-K tripotassium phosphate Chemical compound [K+].[K+].[K+].[O-]P([O-])([O-])=O LWIHDJKSTIGBAC-UHFFFAOYSA-K 0.000 claims 6
- 238000009825 accumulation Methods 0.000 claims 4
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 claims 3
- -1 aluminum compound Chemical class 0.000 claims 3
- 238000000034 method Methods 0.000 claims 3
- 229910000160 potassium phosphate Inorganic materials 0.000 claims 3
- 239000008057 potassium phosphate buffer Substances 0.000 claims 3
- 235000011009 potassium phosphates Nutrition 0.000 claims 3
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical group O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 claims 3
- 239000001488 sodium phosphate Substances 0.000 claims 3
- 229910000162 sodium phosphate Inorganic materials 0.000 claims 3
- 239000012064 sodium phosphate buffer Substances 0.000 claims 3
- 239000002671 adjuvant Substances 0.000 claims 2
- 229910052782 aluminium Inorganic materials 0.000 claims 2
- 239000007979 citrate buffer Substances 0.000 claims 1
- 201000010099 disease Diseases 0.000 claims 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 1
- 238000000338 in vitro Methods 0.000 claims 1
- 208000015181 infectious disease Diseases 0.000 claims 1
- 239000007788 liquid Substances 0.000 claims 1
- 239000000825 pharmaceutical preparation Substances 0.000 claims 1
- 239000008363 phosphate buffer Substances 0.000 claims 1
- 239000000843 powder Substances 0.000 claims 1
- 239000003053 toxin Substances 0.000 claims 1
- 231100000765 toxin Toxicity 0.000 claims 1
- 108700012359 toxins Proteins 0.000 claims 1
- RYFMWSXOAZQYPI-UHFFFAOYSA-K trisodium phosphate Chemical group [Na+].[Na+].[Na+].[O-]P([O-])([O-])=O RYFMWSXOAZQYPI-UHFFFAOYSA-K 0.000 claims 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/02—Bacterial antigens
- A61K39/08—Clostridium, e.g. Clostridium tetani
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/12—Carboxylic acids; Salts or anhydrides thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
- A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
- A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/12—Antidiarrhoeals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55505—Inorganic adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Dermatology (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicinal Preparation (AREA)
- Biotechnology (AREA)
- Peptides Or Proteins (AREA)
- Genetics & Genomics (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Virology (AREA)
- Biomedical Technology (AREA)
- General Engineering & Computer Science (AREA)
- Inorganic Chemistry (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Claims (16)
1. Pripravak koji sadrži toksoid Clostridium difficile i farmaceutski prihvatljive ekscipijente koji sadrže
(a) pufer odabran iz natrijevog ili kalijevog citratnog pufera i natrijevog ili kalijevog fosfatnog pufera; i
(b) saharozu,
naznačen time da navedeni farmaceutski prihvatljivi ekscipijenti povećavaju toplinsku stabilnost toksoida i/ili smanjuju ili odgađaju nakupljanje toksoida, u odnosu na pripravak bez navedenih farmaceutski prihvatljivih ekscipijenata.
2. Pripravak prema zahtjevu 1 naznačen time, da nadalje sadrži formaldehid u koncentraciji od 0.001 do 0.020%.
3. Pripravak prema zahtjevu 1 ili 2, naznačen time da:
(a) navedeni farmaceutski prihvatljivi ekscipijenti redu smanjuju ili odgađaju nakupljanje toksoida za 50% ili više, u odnosu na pripravak kojem nedostaju navedeni farmaceutski prihvatljivi ekscipijenti; ili
(b) navedeni farmaceutski prihvatljivi ekscipijenti povećavaju toplinsku stabilnost toksoida za 0.5°C ili više, u odnosu na pripravak kojem nedostaju navedeni farmaceutski prihvatljivi ekscipijenti.
4. Pripravak prema bilo kojem od zahtjeva 1 do 3, naznačen time da pripravak sadrži toksoid od C. difficile toksina A i B.
5. Pripravak prema zahtjevu 4, naznačen time da:
(a) su toksoidi A i B prisutni u pripravku u omjeru 5:1 (A:B) do 1:5 (A:B); ili
(b) su toksoidi A i B prisutni u pripravku u omjeru 3:1 do 3:2, ili 1:1 (A:B).
6. Pripravak prema bilo kojem od zahtjeva 1 do 5, naznačen time da pripravak je farmaceutski pripravak.
7. Pripravak prema bilo kojem od zahtjeva 1 do 6, naznačen time, da nadalje sadrži adjuvant.
8. Pripravak prema zahtjevu 7, naznačen time da adjuvant sadrži spoj aluminija, proizvoljno pri čemu spoj aluminija je spoj aluminijevog hidroksida.
9. Pripravak prema bilo kojem od zahtjeva 1 do 8, naznačen time da pripravak je
(a) u tekućem obliku; ili
(b) u obliku suhog praška, liofiliziran, osušen smrzavanjem, osušen raspršivanjem ili osušen pjenom.
10. Pripravak prema bilo kojem od zahtjeva 1 do 9, naznačen time da
(a) citratni pufer je natrijev citrat; ili
(b) fosfatni pufer je natrijev fosfat.
11. Pripravak prema bilo kojem od zahtjeva 1 do 9, naznačen time da pripravak sadrži:
(a) toksoide Clostridium difficile A i B, 5-100 mM natrijevog ili kalijevog citrata, 2-20% saharoze, i ≤0.020% formaldehida, pH 5.5-8.5;
(b) toksoide Clostridium difficile A i B, 10-30 mM natrijevog ili kalijevog citrata, 2-10% saharoze, i ≤0.020% formaldehida, pH 6.5-8.0;
(c) toksoide Clostridium difficile A i B, 20 mM natrijevog citrata, 5% saharoze, i 0.016% formaldehida, pH 7.5;
(d) toksoide Clostridium difficile A i B, 5-100 mM natrijevog ili kalijevog fosfata, 2- 20% saharoze, i ≤0.020% formaldehida, pH 5.5-8.5;
(e) toksoide Clostridium difficile A i B, 10-30 mM natrijevog ili kalijevog fosfata, 2- 10% saharoze, i ≤0.020% formaldehida, pH 6.5-8.0; ili
(f) toksoide Clostridium difficile A i B, 20 mM kalijevog fosfata, 5% saharoze, i 0.016% formaldehida, pH 7.5.
12. Pripravak prema bilo kojem od zahtjeva 1 do 9, naznačen time da je pripravak u liofiliziranom obliku i sadrži:
(a) toksoide Clostridium difficile A i B, 10-30 mM natrijevog ili kalijevog citrata, 2-10% saharoze, i ≤0.020% formaldehida, pH 6.5-8.0; ili
(b) toksoide Clostridium difficile A i B, 20 mM natrijevog citrata, 5% saharoze, i 0.016% formaldehida, pH 7.5.
13. Postupak za pripravu pripravka koji sadrži toksoid Clostridium difficile i farmaceutski prihvatljive ekscipijente koji sadrže
(a) pufer odabran od natrijevog ili kalijevog citratnog pufera i natrijevog ili kalijevog fosfatnog pufera; i
(b) saharozu,
naznačen time da navedeni farmaceutski prihvatljivi ekscipijenti povećavaju toplinsku stabilnost toksoida, i/ili smanjuju ili odgađaju nakupljanje toksoida u odnosu na pripravak bez navedenih farmaceutski prihvatljivih ekscipijenata, te postupak sadrži osiguravanje toksoida Clostridium difficile i miješanje toksoida Clostridium difficile s navedenim farmaceutski prihvatljivim ekscipijentima.
14. Pripravak prema bilo kojem od zahtjeva 1 do 12 naznačen time da se koristi u postupku sprječavanja ili liječenja infekcije ili bolesti kod subjekta izazvane s C. difficile.
15. Uporaba kombinacije
(a) pufera odabranog od natrijevog ili kalijevog citratnog pufera i natrijevog ili kalijevog fosfatnog pufera; i
(b) saharozu,
za povećanje in vitro toplinske stabilnosti i/ili smanjivanje ili odgađanje nakupljanja toksoida Clostridium difficile.
16. Uporaba prema zahtjevu 15 naznačena time da su navedene komponente (a) i (b) predviđene u pripravku, a navedeni pripravak je definiran u bilo kojem od zahtjeva 1 do 12.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US97249607P | 2007-09-14 | 2007-09-14 | |
| PCT/US2008/010767 WO2009035707A1 (en) | 2007-09-14 | 2008-09-15 | Pharmaceutical compositions containing clostridium difficile toxoids a and b |
| EP08830210.4A EP2198007B1 (en) | 2007-09-14 | 2008-09-15 | Pharmaceutical compositions containing clostridium difficile toxoids a and b |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HRP20180054T1 true HRP20180054T1 (hr) | 2018-02-09 |
Family
ID=40452372
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HRP20180054TT HRP20180054T1 (hr) | 2007-09-14 | 2018-01-11 | Farmaceutski pripravci koji sadrže toksoide clostridium difficile a i b |
Country Status (21)
| Country | Link |
|---|---|
| US (3) | US9320790B2 (hr) |
| EP (2) | EP2198007B1 (hr) |
| JP (3) | JP5503543B2 (hr) |
| KR (2) | KR101679812B1 (hr) |
| CN (2) | CN101855336B (hr) |
| AU (1) | AU2008299885C1 (hr) |
| BR (1) | BRPI0816790A8 (hr) |
| CA (1) | CA2699435A1 (hr) |
| CY (1) | CY1119979T1 (hr) |
| DK (1) | DK2198007T3 (hr) |
| ES (1) | ES2657485T3 (hr) |
| HR (1) | HRP20180054T1 (hr) |
| HU (1) | HUE037932T2 (hr) |
| IL (1) | IL204366A (hr) |
| MX (1) | MX2010002815A (hr) |
| NO (1) | NO2198007T3 (hr) |
| PL (1) | PL2198007T3 (hr) |
| PT (1) | PT2198007T (hr) |
| RU (1) | RU2550271C2 (hr) |
| SI (1) | SI2198007T1 (hr) |
| WO (1) | WO2009035707A1 (hr) |
Families Citing this family (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SI2198007T1 (en) | 2007-09-14 | 2018-04-30 | Sanofi Pasteur Biologics, Llc | Pharmaceutical compositions containing Clostridium difficile A and B toxoids |
| BR112014004896B1 (pt) | 2010-09-03 | 2023-02-14 | Valneva Usa, Inc. | Polipepttdeo isolado de proteínas de toxina a e toxina b de c. difficile e usos do mesmo |
| GB201105981D0 (en) * | 2011-04-08 | 2011-05-18 | Glaxosmithkline Biolog Sa | Novel process |
| PE20141029A1 (es) * | 2011-04-22 | 2014-09-04 | Wyeth Llc | Composiciones relacionadas con una toxina de clostridium difficile mutante y sus metodos |
| KR101135486B1 (ko) * | 2011-05-25 | 2012-04-13 | 함종욱 | 보툴리눔 에이형 독소의 액상제품 |
| BR122016023101B1 (pt) | 2012-10-21 | 2022-03-22 | Pfizer Inc | Polipeptídeo, composição imunogênica que o compreende, bem como célula recombinante derivada de clostridium difficile |
| CN104903349B (zh) | 2012-11-08 | 2018-10-19 | 十一生物治疗股份有限公司 | Il-6拮抗剂及其应用 |
| JP6290918B2 (ja) | 2012-12-05 | 2018-03-07 | グラクソスミスクライン バイオロジカルズ ソシエテ アノニム | 免疫原性組成物 |
| AP2015008733A0 (en) | 2013-03-14 | 2015-09-30 | Takeda Vaccines Inc | Compositions and methods for live, attenuated alphavirus formulations |
| JP2016519671A (ja) | 2013-03-15 | 2016-07-07 | サノフィ パストゥール インコーポレイテッド | トキソイド、組成物および関連方法 |
| AU2014228956A1 (en) | 2013-03-15 | 2015-10-08 | Sanofi Pasteur, Inc. | Toxoid, compositions and related methods |
| CA2915279A1 (en) | 2013-06-14 | 2014-12-18 | Sanofi Pasteur Inc. | Compositions and methods of immunizing against c. difficile |
| WO2014204303A2 (en) | 2013-06-17 | 2014-12-24 | De Staat Der Nederlanden, Vert. Door De Minister Van Vws, Ministerie Van Volksgezondheid, Welzijn En Sport | Methods for the prevention of aggregation of viral components |
| US9930893B2 (en) * | 2014-02-10 | 2018-04-03 | The Johns Hopkins University | Inhibitors of DXP synthase and methods of use thereof |
| US11142571B2 (en) | 2014-11-07 | 2021-10-12 | Sesen Bio, Inc. | IL-6 antibodies |
| KR20180011784A (ko) | 2015-05-15 | 2018-02-02 | 사노피 파스퇴르 인코포레이티드 | 클로스트리듐 디피실에 대한 면역화 방법 |
| BE1023343B1 (nl) * | 2015-05-20 | 2017-02-09 | Mycartis Nv | Opslagbuffer |
| CA3012350A1 (en) * | 2016-02-23 | 2017-08-31 | Sesen Bio, Inc. | Il-6 antagonist formulations and uses thereof |
| JP7217700B2 (ja) | 2016-09-13 | 2023-02-03 | アラーガン、インコーポレイテッド | 安定化非タンパク質クロストリジウム毒素組成物 |
| KR20210010996A (ko) * | 2018-05-21 | 2021-01-29 | 추가이 세이야쿠 가부시키가이샤 | 유리 용기에 봉입된 동결건조 제제 |
| WO2021255690A2 (en) * | 2020-06-19 | 2021-12-23 | Pfizer Inc. | Immunogenic compositions against clostridioides (clostridium) difficile and methods thereof |
Family Cites Families (35)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4879218A (en) * | 1982-09-13 | 1989-11-07 | Virginia Tech Intellectual Properties, Inc. | Antibody for C.difficile |
| US5736139A (en) * | 1989-10-31 | 1998-04-07 | Ochidian Pharmaceuticals, Inc. | Treatment of Clostridium difficile induced disease |
| JPH03193735A (ja) | 1989-12-22 | 1991-08-23 | Shionogi & Co Ltd | グリコペプチド系抗生物質の安定化組成物 |
| EP0610295A1 (en) * | 1991-10-16 | 1994-08-17 | Schering Corporation | Lipophilic oligosaccharide antibiotic salt compositions |
| WO1994000481A1 (en) | 1992-06-23 | 1994-01-06 | Associated Synapse Biologics | Pharmaceutical composition containing botulinum b complex |
| US5562909A (en) | 1993-07-12 | 1996-10-08 | Massachusetts Institute Of Technology | Phosphazene polyelectrolytes as immunoadjuvants |
| US5902565A (en) * | 1993-12-24 | 1999-05-11 | Csl Limited | Spray dried vaccine preparation comprising aluminium adsorbed immunogens |
| US5512547A (en) * | 1994-10-13 | 1996-04-30 | Wisconsin Alumni Research Foundation | Pharmaceutical composition of botulinum neurotoxin and method of preparation |
| JPH08333277A (ja) | 1995-06-05 | 1996-12-17 | Hoechst Japan Ltd | ヒト血液凝固第ｘｉｉｉ因子の安定化された水性液製剤 |
| JPH11510793A (ja) * | 1995-07-07 | 1999-09-21 | オラバックス インク． | 胃腸病に対する鼻腔内ワクチン接種 |
| US5932223A (en) | 1996-09-26 | 1999-08-03 | Merck & Co., Inc. | Rotavirus vaccine formulations |
| PT892054E (pt) * | 1997-06-20 | 2007-02-28 | Intervet Int Bv | Vacina de clostridium perfringens |
| US6969520B2 (en) * | 1997-10-20 | 2005-11-29 | Acambis Inc. | Active immunization against clostridium difficile disease |
| EP1568378B1 (en) * | 1997-10-20 | 2016-03-16 | Sanofi Pasteur Biologics, LLC | Immunization against Clostridium difficile disease |
| AU754270B2 (en) * | 1997-10-20 | 2002-11-07 | Sanofi Pasteur Biologics, Llc | Passive immunization against clostridium difficile disease |
| US6013635A (en) * | 1998-05-28 | 2000-01-11 | Synsorb Biotech, Inc. | Treatment of C. difficile toxin B associated conditions |
| JP2000117967A (ja) * | 1998-10-16 | 2000-04-25 | Fuji Photo Film Co Ltd | インクジェット記録方法 |
| FR2791895B1 (fr) | 1999-03-23 | 2001-06-15 | Pasteur Merieux Serums Vacc | Utilisation de trehalose pour stabiliser un vaccin liquide |
| KR100922031B1 (ko) * | 1999-04-19 | 2009-10-19 | 글락소스미스클라인 바이오로지칼즈 에스.에이. | 백신 |
| US6599715B1 (en) * | 1999-05-12 | 2003-07-29 | The Regents Of The University Of California | Real time viability detection of bacterial spores |
| US7780967B2 (en) * | 2000-02-08 | 2010-08-24 | Allergan, Inc. | Reduced toxicity Clostridial toxin pharmaceutical compositions |
| EP3192528A1 (en) | 2002-02-14 | 2017-07-19 | Chugai Seiyaku Kabushiki Kaisha | Formulation of anti-il6r antibody-containing solutions comprising a sugar as a stabilizer |
| WO2003088946A1 (en) * | 2002-04-19 | 2003-10-30 | The Regents Of The University Of Michigan | Polymer compositions that stabilize and control the release of formaldehyde-treated vaccine antigens |
| US20040235139A1 (en) * | 2002-12-23 | 2004-11-25 | Demain Arnold L. | Clostridium difficile culture and toxin production methods |
| DE10333317A1 (de) * | 2003-07-22 | 2005-02-17 | Biotecon Therapeutics Gmbh | Formulierung für Proteinarzneimittel ohne Zusatz von humanem Serumalbumin (HSA) |
| JP4671864B2 (ja) | 2003-10-09 | 2011-04-20 | 中外製薬株式会社 | タンパク質溶液の安定化方法 |
| CA2799413A1 (en) * | 2004-07-26 | 2006-02-23 | Merz Pharma Gmbh & Co. Kgaa | Therapeutic composition with a botulinum neurotoxin |
| EP1802349A1 (en) * | 2004-10-13 | 2007-07-04 | Ilypsa, Inc. | Pharmaceutical compositions comprising a toxin-binding oligosaccharide and a polymeric particle |
| FR2881139A1 (fr) * | 2005-01-26 | 2006-07-28 | Agronomique Inst Nat Rech | Composition pour la lyophilisation de proteines |
| BRPI0613001B8 (pt) | 2005-10-06 | 2021-05-25 | Allergan Inc | composições farmacêuticas de toxina clostrídica estabilizada por uma não-proteína |
| US8137677B2 (en) | 2005-10-06 | 2012-03-20 | Allergan, Inc. | Non-protein stabilized clostridial toxin pharmaceutical compositions |
| US20090324647A1 (en) * | 2005-10-11 | 2009-12-31 | Borodic Gary E | Albumin-Free Botulinum Toxin Based Pharmaceutical Compositions Containing a Hyaluronidase and Methods of Use |
| WO2008057550A2 (en) | 2006-11-07 | 2008-05-15 | Sanofi Pasteur Biologics Co. | Stabilization of vaccines by lyophilization |
| SI2198007T1 (en) | 2007-09-14 | 2018-04-30 | Sanofi Pasteur Biologics, Llc | Pharmaceutical compositions containing Clostridium difficile A and B toxoids |
| RU2011126602A (ru) | 2008-12-03 | 2013-01-10 | Берингер Ингельхайм Ветмедика Гмбх | Способ получения вакцин |
-
2008
- 2008-09-15 SI SI200831906T patent/SI2198007T1/en unknown
- 2008-09-15 PT PT88302104T patent/PT2198007T/pt unknown
- 2008-09-15 RU RU2010114730/10A patent/RU2550271C2/ru not_active IP Right Cessation
- 2008-09-15 BR BRPI0816790A patent/BRPI0816790A8/pt not_active IP Right Cessation
- 2008-09-15 CA CA2699435A patent/CA2699435A1/en not_active Abandoned
- 2008-09-15 EP EP08830210.4A patent/EP2198007B1/en active Active
- 2008-09-15 US US12/677,864 patent/US9320790B2/en active Active
- 2008-09-15 HU HUE08830210A patent/HUE037932T2/hu unknown
- 2008-09-15 DK DK08830210.4T patent/DK2198007T3/en active
- 2008-09-15 PL PL08830210T patent/PL2198007T3/pl unknown
- 2008-09-15 MX MX2010002815A patent/MX2010002815A/es unknown
- 2008-09-15 EP EP16174817.3A patent/EP3124044A1/en active Pending
- 2008-09-15 WO PCT/US2008/010767 patent/WO2009035707A1/en active Application Filing
- 2008-09-15 CN CN200880116603.0A patent/CN101855336B/zh active Active
- 2008-09-15 AU AU2008299885A patent/AU2008299885C1/en not_active Ceased
- 2008-09-15 NO NO08830210A patent/NO2198007T3/no unknown
- 2008-09-15 ES ES08830210.4T patent/ES2657485T3/es active Active
- 2008-09-15 KR KR1020107007994A patent/KR101679812B1/ko active IP Right Grant
- 2008-09-15 KR KR1020157036693A patent/KR20160005378A/ko active IP Right Grant
- 2008-09-15 JP JP2010524889A patent/JP5503543B2/ja active Active
- 2008-09-15 CN CN201610227574.1A patent/CN106039299A/zh active Pending
-
2010
- 2010-03-09 IL IL204366A patent/IL204366A/en active IP Right Grant
-
2013
- 2013-11-22 JP JP2013241821A patent/JP6258674B2/ja active Active
-
2016
- 2016-03-29 US US15/083,428 patent/US9687541B2/en active Active
- 2016-10-31 JP JP2016212540A patent/JP2017052773A/ja active Pending
-
2017
- 2017-06-26 US US15/632,480 patent/US10639362B2/en active Active
-
2018
- 2018-01-11 HR HRP20180054TT patent/HRP20180054T1/hr unknown
- 2018-01-23 CY CY20181100084T patent/CY1119979T1/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HRP20180054T1 (hr) | Farmaceutski pripravci koji sadrže toksoide clostridium difficile a i b | |
| AR118273A2 (es) | Excipiente estabilizante para una vacuna de virus completo inactivado | |
| HRP20210547T1 (hr) | Sastavi koji sadrže konjugate lijeka antitijela-duocarmycin | |
| HRP20240231T1 (hr) | Farmaceutske formulacije inhibitora brutonove tirozin kinaze | |
| FI3244917T3 (fi) | Immunogeenisiä koostumuksia pneumokokkirokotteissa käytettäväksi | |
| BRPI0818541B8 (pt) | composição farmacêutica que compreende grânulos incluindo picossulfato de sódio e bicarbonato de potássio e seu processo para a preparação | |
| JP2010539172A5 (hr) | ||
| BRPI0620460B8 (pt) | uso de composição imunogênica para bebês, e, processo para produzir uma vacina | |
| RU2012125254A (ru) | Составы антитела | |
| BR112012022359A2 (pt) | composição imunogênica | |
| WO2010100200A3 (en) | Lyophilised antibody formulation | |
| JP2015134763A5 (hr) | ||
| JP6081436B2 (ja) | ヒドロキシアルキルセルロース微粒子 | |
| DK1418942T3 (da) | Poxvirus-holdige sammensætninger og fremgangsmåde til fremstilling deraf | |
| WO2009000825A3 (en) | Vaccine comprising streptococcus pneumoniae capsular polysaccharide conjugates | |
| WO2008150479A3 (en) | High temperature stable peptide formulation | |
| BR112012011784A2 (pt) | "formulações parenterais de derivados de gencitabina". | |
| BRPI0612669B8 (pt) | composição imunogênica, vacina, composição, e composição liofilizada | |
| BR112013026935A2 (pt) | preparação de base aquosa, composição para limpeza de superfícies de materiais refratários e uso da composição | |
| BRPI0711608B8 (pt) | composição liofilizada, uso de antígeno viral, método de tratamento ou prevenção de vírus associado, método de adaptação de um vírus de uma linhagem celular adequada | |
| MX2011007817A (es) | Formulacion farmaceutica o alimenticia de liberacion controlada y proceso para su preparacion. | |
| WO2013104995A3 (en) | Compositions and methods for treating viral infections | |
| CL2011003113A1 (es) | Composicion adyuvante acuosa que comprende un agonista de tlr-4 y una saponina y un agente de isotonicidad no ionico; proceso para la preparacion de una composicion inmunogenica. | |
| RS53404B (en) | LIQUID FORMULATION OF G-CSF CONJUGATES | |
| EE200200504A (et) | Farmatseutilised preparaadid |